Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Non-Current Deferred Tax Liability (2016 - 2023)

Historic Non-Current Deferred Tax Liability for Amphastar Pharmaceuticals (AMPH) over the last 11 years, with Q3 2023 value amounting to $201000.0.

  • Amphastar Pharmaceuticals' Non-Current Deferred Tax Liability fell 1694.21% to $201000.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $201000.0, marking a year-over-year decrease of 1694.21%. This contributed to the annual value of $144000.0 for FY2022, which is 7303.37% down from last year.
  • Latest data reveals that Amphastar Pharmaceuticals reported Non-Current Deferred Tax Liability of $201000.0 as of Q3 2023, which was down 1694.21% from $201000.0 recorded in Q2 2023.
  • In the past 5 years, Amphastar Pharmaceuticals' Non-Current Deferred Tax Liability ranged from a high of $2.9 million in Q3 2021 and a low of $144000.0 during Q4 2022
  • For the 5-year period, Amphastar Pharmaceuticals' Non-Current Deferred Tax Liability averaged around $726105.3, with its median value being $755000.0 (2021).
  • In the last 5 years, Amphastar Pharmaceuticals' Non-Current Deferred Tax Liability soared by 25249.09% in 2021 and then tumbled by 9165.8% in 2022.
  • Quarter analysis of 5 years shows Amphastar Pharmaceuticals' Non-Current Deferred Tax Liability stood at $867000.0 in 2019, then dropped by 14.53% to $741000.0 in 2020, then dropped by 27.94% to $534000.0 in 2021, then plummeted by 73.03% to $144000.0 in 2022, then soared by 39.58% to $201000.0 in 2023.
  • Its Non-Current Deferred Tax Liability was $201000.0 in Q3 2023, compared to $201000.0 in Q2 2023 and $178000.0 in Q1 2023.